TheraVet, a pioneering company in the management of osteoarticular diseases in companion animals, has commercially launched BIOCERA-VET – Osteosarcoma in Belgium, France and The Netherlands.
Canine osteosarcoma is the most frequent and most aggressive dog primary bone cancer affecting more than 30,000 patients per year in Europe and in United States. Currently, osteosarcoma management is mainly performed by amputation or limb-sparing surgeries associated with chemotherapy. Unfortunately these invasive approaches are not always the optimal option for the pets and the owners looking for more palliative and qualitative alternatives. BIOCERA-VET – Osteosarcoma can be used in a minimally invasive surgical technique consisting of cementing the tumoral site with BIOCERA-VET.
With this new step, TheraVet is pursuing, as planned, its commercial expansion strategy with the launch of the second product of its bone substitute product line, BIOCERA-VET – Osteosarcoma, in Belgium, France and in The Netherlands.
Based on promising efficacy and safety results disclosed earlier this year, BIOCERA-VET- Osteosarcoma represents a game-changer option in the management of canine osteosarcoma.
Enrico Bastianelli, Chief Executive Officer of TheraVet, said, “Based on solid clinical evidences, it can now be said that BIOCERA-VET – Osteosarcoma will meet an important need in the palliative management of canine osteosarcoma by relieving pain and improving the quality of life of our beloved pets through a minimally invasive approach. We are therefore very happy to make it available.”